Pfizer

Is Pfizer overvalued or undervalued?

As of December 12, 2023, Pfizer is considered very expensive and overvalued with a PE ratio of 41.15 and an EV to EBITDA of 32.17, significantly higher than peers like Sun Pharma and Cipla, despite outperforming the Sensex in the short term.

As of 12 December 2023, Pfizer's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 41.15, an EV to EBITDA of 32.17, and a PEG ratio of 2.56, all of which are substantially higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla stands at a much lower PE of 22.99 and an EV to EBITDA of 15.93, showcasing that Pfizer's valuation metrics are considerably elevated. Additionally, Pfizer's recent stock performance has outpaced the Sensex over the past month and year, with returns of 32.93% and 14.79%, respectively, although it still lags behind the Sensex over longer periods.

What does Pfizer do?

Pfizer Limited is a large-cap pharmaceutical company in India, involved in manufacturing, marketing, and exporting pharmaceutical products. As of March 2025, it reported net sales of 592 Cr and a net profit of 331 Cr, with a market cap of Rs 26,116 Cr.

Overview:<BR>Pfizer Limited is engaged in the manufacturing, marketing, trading, and export of pharmaceutical products within the Pharmaceuticals & Biotechnology industry and is categorized as a Large Cap company.<BR><BR>History:<BR>Pfizer Limited was incorporated in India and has established itself as a pioneer in clinical research within the country. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 592 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 331 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 26,116 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 42.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.60%<BR>- Debt Equity: -0.60<BR>- Return on Equity: 16.88%<BR>- Price to Book: 7.08<BR><BR>Contact Details:<BR>Address: The Capital 1802/1901 Plot-C70, G Bl Bandra Kurla Cpx Bandra-E Mumbai Maharashtra : 400051<BR>Tel: 91-22-66932000<BR>Email: contactus.india@pfizer.com<BR>Website: http://www.pfizerindia.com

Has Pfizer declared dividend?

Yes, Pfizer has declared a dividend of 350%, amounting to 35 per share, with an ex-date of August 21, 2024. The dividend yield is 0.6%, and total returns over various periods have shown positive performance, particularly in the long term.

Pfizer Ltd. has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 350%<BR>- Amount per share: 35<BR>- Ex-date: 21 Aug 24<BR><BR>Dividend Yield: 0.6%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 9.39%, with no dividend return, resulting in a total return of 9.39%.<BR><BR>Over the past year, the price return was 17.0%, with a dividend return of 0.71%, leading to a total return of 17.71%.<BR><BR>In the 2-year period, the price return was 44.62%, with a dividend return of 1.04%, culminating in a total return of 45.66%.<BR><BR>For the 3-year period, the price return was 36.06%, with a dividend return of 2.55%, resulting in a total return of 38.61%.<BR><BR>In the 4-year period, the price return was 10.34%, with a dividend return of 1.97%, leading to a total return of 12.31%.<BR><BR>Over the last 5 years, the price return was 39.69%, with a dividend return of 2.87%, resulting in a total return of 42.56%.<BR><BR>Overall, Pfizer's recent dividend declaration reflects a significant return to shareholders, and the total returns over various periods indicate a generally positive performance, particularly in the longer term.

Who are the peers of the Pfizer?

Pfizer's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Emcure Pharma, Wockhardt, OneSource Specialty, ERIS Lifescience, and Alembic Pharma. In terms of performance, Wockhardt has the highest 1-year return at 175.09%, while Pfizer's return is 20.11%.

Peers: The peers of Pfizer are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Emcure Pharma, Wockhardt, OneSource Speci., ERIS Lifescience, and Alembic Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Emcure Pharma, OneSource Speci., ERIS Lifescience, and Alembic Pharma, while Average management risk is found at Wockhardt. Growth is excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and OneSource Speci., while below average growth is noted for Divi's Lab., Pfizer, Torrent Pharma, Emcure Pharma, ERIS Lifescience, and Alembic Pharma. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Pfizer, and ERIS Lifescience, while good capital structure is noted for Torrent Pharma and Emcure Pharma, and below average capital structure is found at Wockhardt.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wockhardt at 175.09%, while the peer with the lowest is Emcure Pharma, which has no available data. Pfizer's 1-year return is 20.11%, which is significantly lower than Wockhardt's but higher than Emcure Pharma's. Additionally, Emcure Pharma and Alembic Pharma have negative six-month returns.

Who are in the management team of Pfizer?

As of March 2023, Pfizer's management team includes Prajeet Nair (Company Secretary), Milind Anil Patil (Executive Director, Finance), Meenakshi Nevatia (Managing Director), and several independent directors, including Pradip P Shah (Chairman). The team combines executive and independent leadership for effective governance.

As of March 2023, the management team of Pfizer includes the following individuals:<BR><BR>1. Prajeet Nair - Company Secretary & Compliance Officer<BR>2. Uday Khanna - Independent Director<BR>3. Sunil Lalbhai - Independent Director<BR>4. Milind Anil Patil - Executive Director (Finance)<BR>5. Meena Ganesh - Independent Director<BR>6. Samir Kazi - Executive Director<BR>7. Pradip P Shah - Chairman & Independent Director<BR>8. Meenakshi Nevatia - Managing Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and operational leadership of the company.

Who are the top shareholders of the Pfizer?

The top shareholders of Pfizer include Pfizer East India B V with 39.75%, mutual funds holding 11.59%, individual investors at 12.34%, and Nippon Life India Trustee Ltd as the largest public shareholder with 4.17%. Foreign Institutional Investors (FIIs) hold 2.18% of the shares.

The top shareholders of Pfizer include Pfizer East India B V, which holds the largest share at 39.75%. Other significant shareholders include mutual funds, which collectively hold 11.59% through 24 schemes, and individual investors, who account for 12.34% of the shares. Additionally, Nippon Life India Trustee Ltd is the highest public shareholder with a 4.17% stake. Foreign Institutional Investors (FIIs) hold 2.18% of the shares through 67 different entities.

How big is Pfizer?

As of 24th July, Pfizer Ltd. has a market capitalization of 24,201.00 Cr and reported net sales of 2,281.35 Cr and a net profit of 767.60 Cr over the latest four quarters. Data for Shareholder's Funds and Total Assets is unavailable.

As of 24th July, <BR><BR>Market Cap: Pfizer Ltd. has a market capitalization of 24,201.00 Cr and is classified as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of net sales for the latest four quarters is 2,281.35 Cr, while the sum of net profit for the same period is 767.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is the latest annual period. However, data for Shareholder's Funds and Total Assets is unavailable.

When is the next results date for Pfizer?

The next results date for Pfizer is November 12, 2025.

The next results date for Pfizer is scheduled for November 12, 2025.

How has been the historical performance of Pfizer?

Pfizer's historical performance shows fluctuating net sales, increasing from 681.70 Cr in 2008 to 772.27 Cr in 2009, but profitability declined, with profit after tax dropping from 299.58 Cr to 137.12 Cr due to rising expenditures. Despite sales growth, the company faced challenges in managing costs, leading to reduced profit margins.

Answer:<BR>The historical performance of Pfizer shows a trend of fluctuating net sales and profits over the years reported.<BR><BR>Breakdown:<BR>Pfizer's net sales increased from 681.70 Cr in November 2008 to 772.27 Cr in November 2009, indicating a positive growth trend. Other operating income also rose slightly from 22.90 Cr in November 2008 to 24.37 Cr in November 2009. Total operating income followed this upward trajectory, reaching 796.64 Cr in November 2009, up from 704.60 Cr the previous year. However, total expenditure increased significantly from 552.36 Cr in November 2008 to 638.47 Cr in November 2009, leading to an operating profit (PBDIT) of 229.22 Cr in November 2009, which was a modest increase from 222.35 Cr in November 2008. The profit before tax saw a notable decline from 419.13 Cr in November 2008 to 210.01 Cr in November 2009, and consequently, profit after tax also decreased from 299.58 Cr to 137.12 Cr in the same period. This resulted in a drop in earnings per share from 100.4 to 45.95. The operating profit margin and profit after tax margin also decreased, reflecting a decline in profitability. Overall, while Pfizer experienced growth in sales, the profitability metrics suggest challenges in managing costs effectively during this period.

Is Pfizer technically bullish or bearish?

As of December 1, 2025, Pfizer's technical stance is mildly bearish due to bearish MACD, Bollinger Bands, and KST indicators on weekly and monthly charts, despite a mildly bullish signal from daily moving averages.

As of 1 December 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance for Pfizer is mildly bearish. Key indicators driving this stance include a bearish MACD on both weekly and monthly time frames, bearish Bollinger Bands across both time frames, and a bearish KST on the weekly chart. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish sentiment in the weekly and monthly indicators. Additionally, the stock has underperformed compared to the Sensex across multiple time frames, further supporting the bearish outlook.

Are Pfizer Ltd. latest results good or bad?

Pfizer Ltd.'s latest results show strong revenue growth with net sales up 6.52% quarter-on-quarter, but net profit declined by 1.42% from the previous quarter, raising concerns about profitability sustainability. Overall, the results are mixed, highlighting both positive revenue trends and challenges in maintaining profit margins.

Pfizer Ltd.'s latest results present a mixed picture. In Q2 FY26, the company reported net sales of ₹642.34 crores, which reflects a healthy increase of 6.52% quarter-on-quarter and 9.13% year-on-year. This indicates solid revenue growth and marks the highest quarterly revenue figure in recent periods.<BR><BR>However, the net profit for the same quarter was ₹189.02 crores, which represents a slight decline of 1.42% compared to the previous quarter, although it shows a significant year-on-year improvement of 19.37%. This decline in net profit raises concerns about the sustainability of the company's profitability, especially considering the pressures on margins.<BR><BR>The operating margin improved to 35.80%, indicating better cost management, but the profit after tax margin contracted, suggesting some challenges in maintaining profitability amidst rising costs. Additionally, the significant drop in other income further highlights the company's reliance on its core pharmaceutical operations for profitability.<BR><BR>Overall, while Pfizer Ltd. demonstrates strong revenue growth and maintains a robust capital efficiency profile, the decline in net profit and the pressures on margins indicate that the results are not entirely positive. Investors may need to weigh these factors carefully when assessing the company's performance and future outlook.

Should I buy, sell or hold Pfizer Ltd.?

Why is Pfizer Ltd. falling/rising?

As of 16-Mar, Pfizer Ltd.'s stock price is rising to 4,689.40, reflecting a 1.62% increase. Despite this short-term gain and a favorable dividend yield, long-term growth concerns persist due to slow sales growth and high valuation metrics.

As of 16-Mar, Pfizer Ltd.'s stock price is rising, currently at 4,689.40, with a change of 74.9 (1.62%) upwards. This increase can be attributed to several factors. Notably, the stock has outperformed its sector by 2.74% today and has experienced a trend reversal, gaining after three consecutive days of decline. Additionally, the stock reached an intraday high of Rs 4,950, reflecting a significant increase of 7.27%.<BR><BR>Despite the positive movement today, it is important to consider the broader context. Over the past week, the stock has decreased by 1.74%, and over the past month, it has fallen by 6.40%. However, on a year-to-date basis, Pfizer has shown a decline of 5.88%, which is better than the Sensex's decline of 11.40%. Over the past year, Pfizer's stock has generated a return of 15.66%, significantly outperforming the Sensex's 2.27%.<BR><BR>The stock's performance is also supported by a high dividend yield of 3.58%, which can attract investors looking for income. However, there are concerns regarding long-term growth, as net sales have only grown at an annual rate of 2.39% over the last five years, and the company has a high Price to Book Value ratio of 5.6, indicating a potentially expensive valuation.<BR><BR>In summary, while Pfizer Ltd. is currently experiencing a rise in stock price due to short-term performance improvements and a favorable dividend yield, the long-term outlook remains cautious due to slower growth metrics and high valuation concerns.

Which are the latest news on Pfizer?